Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB000928 Monotherapy or Combination With Ruxolitinib in Anemia Due to Myeloproliferative Disorders
2023-503624-83-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of zilurgisertib in anemia of myelofibrosis, myelofibrosis (MF) and Myeloproliferative neoplasm-associated anemia (2 arms), sponsored by Incyte. Started Aug 2021; status: completed.
02
Drugs
zilurgisertib
03
Conditions
anemia of myelofibrosismyelofibrosis (MF)Myeloproliferative neoplasm-associated anemia
Beyond the preview
Go deeper on 2023-503624-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503624-83-00.